Super Practical Knowledge—Screening Stable Transfected Cell Lines with Puromycin

 

Puromycin is an aminoglycoside antibiotic produced by Streptomyces alboniger. It is an analog of the 3' end of the aminoacyl-tRNA molecule and can bind to the A site of the ribosome, incorporating into the extending peptide chain, disrupting peptide translocation on the ribosome, causing premature chain termination during translation, and thus inhibiting protein synthesis.

Figure 1 Structural formula of Puromycin (CAS NO. 53-79-2)

The pac gene, encoding puromycin N-acetyltransferase (pac), was found in the Puromycin-producing bacterium Streptomyces alboniger, conferring resistance to puromycin. This characteristic is now widely used to screen mammalian stable transfected cell lines carrying plasmids with the pac gene. The widespread use of puromycin in the screening of stable cell lines is related to the characteristics of lentiviral vectors, most of which carry the pac gene in commercial lentiviral vectors. In certain specific cases, puromycin can also be used to screen E. coli strains transformed with plasmids carrying the pac gene. Puromycin acts rapidly and can quickly cause cell death at low concentrations. Adherent mammalian cells are sensitive to concentrations of 2-5 µg/mL of puromycin, while suspension cells are already sensitive to concentrations as low as 0.5-2 µg/mL of puromycin. Mammalian cells with stable resistance to puromycin can be generated within a week.

Stable Cell Line Screening

Experimental Principle

By cloning exogenous DNA/shRNA into a vector carrying the pac gene, the recombinant vector is transfected into host cells and integrated into their chromosomes, stably transmitted with cell division, and finally screened with puromycin.

Preparation and Pre-experiment

1 Recommended Usage Concentrations

Mammalian cells: 1-10 μg/mL, the optimal concentration needs to be determined by pre-experiment.

E.coli: For screening stable transformed E. coli carrying the pac gene on LB agar medium, use a concentration of 125 μg/mL. Precise pH adjustment is required for puromycin screening of E. coli stable transformants.

2 Dissolution Method

Dissolve puromycin in distilled water to prepare a 50 mg/mL stock solution, filter sterilize with a 0.22 μm filter, aliquot, and store at -20°C.

3 Determination of Puromycin Kill Curve (using shRNA transfection or lentiviral transduction as an example)

The effective screening concentration of puromycin is related to cell type, growth status, cell density, cell metabolism, and the cell cycle position. It is crucial to determine the minimum concentration of puromycin that kills untransfected cells. It is essential to perform a Puromycin gradient screening pre-experiment for the first experiment to establish a kill curve.

  • Plate cells at a density of 5~8×104cells/well in a 24-well plate and culture overnight.
  • Prepare screening medium: Fresh medium containing different concentrations of puromycin (e.g., 0-15 μg/mL, at least 5 gradients).
  • Replace with freshly prepared screening medium, continue culturing, and observe cell growth, changing the fresh screening medium every 2-3 days.
  • Observe cell survival daily; the drug concentration that effectively kills all non-transfected cells within 4-6 days is the minimum concentration.

Screening of Stable Transfectants

  • After lentiviral infection for 48-72h (70-80% confluence), culture cells in medium containing an appropriate concentration of Puromycin for at least 48h. When all cells in the non-transfected control group with puromycin die, the remaining cells in the virus-infected group are all positive cells.

【Note】: ① The effect of antibiotics is most pronounced when cells are in an active division phase. The efficacy of antibiotics will be significantly reduced if the cells are too dense. The cell density should not exceed 25%. ② Observe the cell growth status daily; puromycin screening requires at least 48 h, and the effective concentration of puromycin screening usually lasts from 3 to 10 days. The higher the MOI of the virus, the more copies of shRNA and puromycin resistance gene each cell contains. When performing puromycin screening, the higher the MOI, the more pac copies the cells contain, and the higher the concentration of puromycin they can tolerate. Adjust the concentration of puromycin to screen transfected cells, but the concentration of puromycin should not be lower than the minimum effective concentration of the kill curve;

  • Add culture medium containing the minimum concentration of Puromycin to expand cells, and after the qPCR test results are qualified, proceed with cryopreservation.

Products name

Cat#

Specification

Appearance

Puromycin Dihydrochloride

CAS:58-58-2

60210ES25

25 mg

White to a white-like powder

60210ES60

100 mg

60210ES72

250 mg

60210ES76

500 mg

60210ES80

1 g

Puromycin

(Solution 10 mg/mL)

CAS:58-58-2

60209ES10

1×1 mL

Solution(10 mg/mL in H2O)

60209ES50

5×1 mL

60209ES60

10×1 mL

60209ES76

50×1 mL

Product Recommendation

Publications by Customers Using This Product (Partial Statistics: Some)

[1] Zhang D, Liu Y, Zhu Y, et al. A non-canonical cGAS -STING-PERK pathway facilitates the translational program critical for senescence and organ fibrosis. Nat Cell Biol . 2022;24(5):766- 782. doi:10.1038/s41556-022-00894-z (IF:28.824)

[2] Lu T, Zhang Z, Zhang J, et al. CD73 in small extracellular vesicles derived from HNSCC defines tumor-associated immunosuppression mediated by macrophages in the microenvironment. J Extracell Vesicles . 2022;11(5):e12218. doi:10.1002/jev2.12218 (IF:25.841)

[3] Meng F, Yu Z, Zhang D, et al. Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. Mol Cell . 2021;81(20):4147-4164.e7.doi: 10.1016/j.molcel.2021.07.040 (IF:17.970)

[ 4] Chen S, Liu S, Wang J, et al. TBK1-Mediated DRP1 Targeting Confers Nucleic Acid Sensing to Reprogram Mitochondrial Dynamics and Physiology. Mol Cell . 2020;80(5):810-827.e7.doi:10.1016 /j.molcel.2020.10.018 (IF:15.584)

[5] Zhao Q, Zheng K, Ma C, et al. PTPS Facilitates Compartmentalized LTBP1 S-Nitrosylation and Promotes Tumor Growth under Hypoxia. Mol Cell . 2020;77(1 ):95-107.e5. doi:10.1016/j.molcel.2019.09.018 (IF:14.548)

[6] Mo J, Liu F, Sun X, et al. Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists. Cancer Res . 2021;81(11):3105-3120. doi:10.1158/0008-5472.CAN-20-3186 (IF:12.701)

[7] Zou Y, Wang A, Shi M, et al al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc . 2018;13(10):2362-2386. doi:10.1038/s41596-018-0042-5 (IF:12.423)

[8] Mao L, Chen J, Lu X, et al. Proteomic analysis of lung cancer cells reveals a critical role o f BCAT1 in cancer cell metastasis. Theranostics. 2021;11(19):9705-9720. Published 2021 Sep 27. doi:10.7150/thno.61731 (IF:11.556)

[9] Han L, Zhang F, Liu Y, et al al. Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection. Clin Transl Med. 2022;12(6):e850. doi:10.1002/ctm2.850 (IF:11.492 )

[10] Zhang M, Liu F, Zhou P, et al. The MTOR signaling pathway regulates macrophage differentiation from mouse myeloid progenitors by inhibiting autophagy. Autophagy . 2019;15(7):1150-1162. doi:10.1080/15548627.2019. 1578040 (IF:11.059)

[11] Zhang S, Yang Z, Bao W, et al. SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC. Autophagy . 2020;16(4):735 -749. doi:10.1080/15548627.2019.1632122 (IF:11.059)

[12] Zhang Y, Ding H, Wang X, et al. MK2 promotes Tfcp2l1 degradation via β-TrCP ubiquitin ligase to regulate mouse embryonic stem cel l self-renewal. Cell Rep . 2021;37(5):109949. doi:10.1016/j.celrep.2021.109949 (IF:9.423)

[13] Jiang Y, Dong Y, Luo Y, et al. AMPK-mediated Phosphorylation on 53BP1 promotes c-NHEJ. Cell Rep . 2021;34(7):108713. doi:10.1016/j.celrep.2021.108713 (IF:9.423)

[14] Sun Q, Ye Y, Gui A, et al. MORTALIN-Ca 2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma. Cancer Lett . 2022;537:215678. doi:10.1016/j.canlet.2022.215678 (IF:8.679)

[15] Jin R, Zhao A , Han S, et al. The interaction of S100A16 and GRP78 actives endoplasmic reticulum stress-mediated through the IRE1α/XBP1 pathway in renal tubulointerstitial fibrosis. Cell Death Dis . 2021;12(10):942. Published 2021 Oct 13. doi: 10.1038/s41419-021-04249-8 (IF:8.469)

[16] Zhang P, Zhang Z, Fu Y, et al. K63-linked ubiquitination of DYRK1A alleviates by TRAF2 Sprouty 2-mediated degradation of EGFR. Cell Death Dis . 2021;12(6):608. Published 2021 Jun 11. doi:10.1038/s41419-021-03887-2 (IF:8.469)

[17] Zhao T, Li Y, Shen K, Wang Q, Zhang J. Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC. Cell Death Dis. 2021;13(1):4. Published 2021 Dec 17. doi: 10.1038/s41419-021-04174-w (IF:8.469)

[18] Zhou R, Wu Q, Wang M, et al. The protein phosphatase PPM1A dephosphorylates and activates YAP to govern mammalian intestinal and liver regeneration. PLoS Biol . 2021; 19(2):e3001122. Published 2021 Feb 25. doi:10.1371/journal.pbio.3001122 (IF:8.029)

[19] Wu S, Wang S, Lin X, Yang S, Ba X, Xiong D, Xiao L, Li R. Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells. Phytomedicine. 2024 Feb;124:155308. doi: 10.1016/j.phymed.2023.155308. (IF:7.9)

[20] Shen K, Song W, Wang H, Wang L, Yang Y, Hu Q, Ren M, Gao Z, Wang Q, Zheng S, Zhu M, Yang Y, Zhang Y, Wei C, Gu J. Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score. Cell Death Discov. 2023 Oct 25;9(1):397. doi: 10.1038/s41420-023-01678-6.  (IF:7.0)

Related Products

Product name

Cat#

Specification

Ciprofloxacin hydrochloride

60201ES05/25/60

5/25/100g

Ampicillin, Sodium Salt

60203ES10/60

10/100g

Doxycycline hyclate

60204ES03/08/25

1/5/25g

Chloramphenicol, USP Grade

60205ES08/25/60

5/25/100g

Kanamycin Sulfate

60206ES10/60

10/100g

Tetracyclin HCl Tetracycline hydrochloride (USP)

60212ES25/60

25/100g

Vancomycin Hydrochloride

60213ES60/80/90

100mg/1g/5g

Gentamycin Sulfate Salt

60214ES03/08/25

1/5/25g

Spectinomycin Hydrochloride

60215ES08

5g

Phleomycin (20 mg/mL in solution)

60217ES20/60

20/5×20mg

Blasticidin S (Blasticidin)

60218ES10/60

10/10×10mg

Nystatin

60219ES08

5g

G418 Sulfate (Geneticin)

60220ES03/08

1/5g

Puromycin (Solution 10 mg/mL)

60209ES10/50/60/76

1×1 /5 ×1 / 1 0 ×1 /50 ×1 mL

Puromycin Dihydrochloride

60210ES25/60/72/76/80

25/100/250/500 mg / 1 g

Hygromycin B (50 mg/mL)

60224ES03

1 g (20 mL)/10×1 g (20 mL)

Hygromycin B

60225ES03/10

1/10g

Erythromycin

60228ES08/25

5/25g

Timentin

60230ES07/32

3.2/10×3.2g

Aureobasidin A (AbA)

60231ES03/08/10

1/5×1/10×1mg

Polymyxin B Sulfate

60242ES03/10

1/10MU